At the 2024 Menopause Society meeting, JoAnn Pinkerton, MD, highlighted phase 3 long-term safety data of elinzanetant from the OASIS 3 trial.
At the 2024 Menopause Society meeting being held in Chicago, Illinois through September 14, 2024, JoAnn Pinkerton, MD, FACOG, NCMP, joined us to discuss phase 3 data of elinzanetant from the OASIS 3 trial.
The trial sought to evaluate the safety and efficacy of elinzanetant in postmenopausal women with moderate-to-severe vasomotor symptoms (VMS).
"OASIS 3 is a clinical trial that built on OASIS 1 and 2, which were 26-week trials that were just published in JAMA," said Pinkerton, who is a professor of Obstetrics and Gynecology at The University of Virginia Health System in Charlottesville, Virginia.
"OASIS 3 was a longer clinical trial, 52 weeks, that took primarily women who are having bothersome menopausal symptoms of moderate to severe, and they observed them over a year for safety and efficacy. The primary endpoint was the reduction in hot flushes from baseline to 12 weeks, but then we really wanted to look at the safety and efficacy across 52 weeks," Pinkerton said.
"The good news was that Oasis met its primary objective," she added. "Hot flashes were significantly reduced at 12 weeks in this population of women who were not as severe as those in OASIS 1 and 2—more like you would see in your clinical practice—significantly reduced compared to placebo at 12 weeks, and then maintained that efficacy throughout the 52 weeks.
Click here for more coverage from The Menopause Society Meeting.
Reference:
Panay N, Joffe H, Maki P, et al. Efficacy and Long-term Safety of Elinzanetant for the Treatment of VMS Associated with Menopause: A Phase 3 Randomized Trial (OASIS 3). Abstract. Presented at: The Menopause Society 2024 Annual Meeting. September 10 - September 14, 2024. Chicago, Illinois.
Later-onset menopause linked to lower heart disease risk
February 10th 2025A new study from the University of Colorado Boulder suggests that women who experience menopause at age 55 years or later may have significantly better vascular health and a reduced risk of heart attacks and strokes.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Menopausal hormone therapy linked to increased risk of SLE and SSc
February 7th 2025A new study found that menopausal hormone therapy is associated with a higher risk of systemic lupus erythematosus and systemic sclerosis, emphasizing the role of female sex hormones in immune-mediated diseases.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
AI helps improve detection of congenital heart defects on prenatal ultrasounds
January 31st 2025AI-assisted software improves clinicians' detection of congenital heart defects in prenatal ultrasounds, enhancing accuracy, confidence, and speed, according to a study presented at SMFM's Annual Pregnancy Meeting.
Read More